Myriant Technologies, a Quincy, MA-based developer of biochemicals, revealed its intention to raise $125 million in an initial public offering, according to documents filed with the SEC. The company plans to put the proceeds toward completing a plant in Louisiana, as well as working capital, research and development, and general corporate purposes. It reported a $16 million net loss on $14 million in revenue for 2010. In January Myriant brought in $60 million in equity financing from PTT Chemical Public Company.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
